Free tool
Drugs in development
Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations
Drugs in development
3,685
Not FDA-approved
In Phase 3
1,424
Highest phase reached
Matching your filters
28
28 drugs in development
Names, sponsors and conditions come from the trial records. Click a drug for its trials.
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- EnvudeucitinibPhase 34 trials
Alumis Inc · Plaque Psoriasis, SLE
- ICP-332Phase 34 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Non Segmental Vitiligo, Chronic Spontaneous Urticaria (CSU), Atopic Dermatitis
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
- ICP-488Phase 33 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Plaque Psoriasis Patients, Primary Sjögren's Syndrome, Cutaneous Lupus Erythematosus (CLE)
- SHR-1314Phase 33 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Active Non-radiographic Axial Spondyloarthritis, Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis, Psoriatic Arthritis
- CMS-D001Phase 32 trials
Dermavon Holdings Limited · Moderate to Severe Plaque Psoriasis, Moderate to Severe Atopic Dermatitis
- HS-20137QX004NPhase 32 trials
Hansoh BioMedical R&D Company · Moderate-to-severe Plaque Psoriasis
- NetakimabPhase 32 trials
Biocad · Plaque Psoriasis
- PicankibartPhase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Psoriatic Arthritis, Plaque Psoriasis
- piclidenosonPhase 32 trials
Can-Fite BioPharma · Plaque Psoriasis, Lowe Syndrome
- SYHX1901Phase 32 trials
CSPC Ouyi Pharmaceutical Co., Ltd. · Moderate to Severe Plaque Psoriasis, Severe Alopecia Areata
- WD-890Phase 32 trials
Zhejiang Wenda Pharma Technology LTD. · Brief Description of Focus of Study, Moderate to Severe Plaque Psoriasis
- Blinded EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
- GNR-068Phase 31 trial
AO GENERIUM · Plaque Psoriasis
- Open-Label EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
- QL2106Phase 31 trial
Qilu Pharmaceutical Co., Ltd. · Plaque Psoriasis
- SHR-1139Phase 25 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Moderate to Severe Plaque Psoriasis, Palmoplantar Pustulosis of Adults, Pyoderma Gangrenosum
- ORKA-002Phase 23 trials
Oruka Therapeutics, Inc. · Plaque Psoriasis, Hidradenitis Suppurativa (HS)
- RSS0393Phase 23 trials
Jiangsu HengRui Medicine Co., Ltd. · Psoriatic Subjects, Plaque Psoriasis in Children, Plaque Psoriasis in Adolescents
- HSK47388Phase 22 trials
Haisco Pharmaceutical Group Co., Ltd. · Plaque Psoriasis, Ulcerative Colitis (UC)
- ORKA-001Phase 22 trials
Oruka Therapeutics, Inc. · Plaque Psoriasis
- COL-5671-PROPhase 21 trial
Coultreon Biopharma · Plaque Psoriasis
- CS32582Phase 21 trial
Chipscreen Biosciences, Ltd. · Plaque Psoriasis
- HS-20118Phase 21 trial
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Moderate to Severe Plaque Psoriasis
- LY3972406Phase 21 trial
Eli Lilly · Plaque Psoriasis
- LY4100511Phase 21 trial
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · Plaque Psoriasis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.